Mount Sinai DoctorsTreats Children
Accepting New Patients
Oren Becher, MD
Pediatrics, Pediatric Hematology-Oncology
About Me
Oren Becher, MD, is chief of the Jack Martin Fund Division of Pediatric Hematology-Oncology at the Mount Sinai Kravis Children’s Hospital’s Children’s Cancer Program in the Jack and Lucy Clark Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, where he is an attending physician. Dr. Becher is a board-certified Pediatric Hematologist/Oncologist. He has been active in academic medicine since 2007. He treats blood disorders and cancer in children, adolescents, and young adults.
Dr. Becher earned his BA magna cum laude from the University of Pennsylvania, and MD from Johns Hopkins School of Medicine. He completed his pediatric residency at Children’s National Medical Center in Washington, DC and a fellowship in Pediatric Hematology-Oncology and Pediatric Neuro-Oncology at Memorial Sloan-Kettering Cancer Center in NYC. Dr. Becher served on the faculty at Duke University and Northwestern University prior to relocating to Mount Sinai.
Dr. Becher’s research, funded by the National Institutes of Health (NIH), uses genetically engineered mouse models to identify more effective therapies for children with DIPG, or diffuse intrinsic pontine glioma. DIPG is an incurable childhood brain cancer that arises in the brainstem. Dr. Becher developed the first genetically engineered mouse models for DIPG and co-discovered that 25% of DIPGs harbor somatic activating mutations in a gene called ACVR1 or ALK2, thus identifying a novel therapeutic target. His research team is currently evaluating novel therapies in these models and are also developing novel models for other types of childhood brain cancers. Dr. Becher’s research has been published in top scientific journals, and he serves on the advisory board of several leading pediatric cancer foundations. Dr. Becher has also initiated clinical trials for children with solid tumors evaluating novel therapies.
In addition to directing his research group, Dr. Becher provides patient care as a pediatric hematologist-oncologist and supervises pre- and post-doctoral trainees. He serves as a grant reviewer for several organizations including NIH. Among the numerous awards he has won, he has been named a Damon Runyon Clinical Investigator, a St. Baldrick’s Scholar, a Forbeck Scholar, and a Hyundai Hope on Wheels Scholar.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Research Topics
Pediatrics
Multi-Disciplinary Training Areas
Neuroscience [NEU]
About Me
Oren Becher, MD, is chief of the Jack Martin Fund Division of Pediatric Hematology-Oncology at the Mount Sinai Kravis Children’s Hospital’s Children’s Cancer Program in the Jack and Lucy Clark Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, where he is an attending physician. Dr. Becher is a board-certified Pediatric Hematologist/Oncologist. He has been active in academic medicine since 2007. He treats blood disorders and cancer in children, adolescents, and young adults.
Dr. Becher earned his BA magna cum laude from the University of Pennsylvania, and MD from Johns Hopkins School of Medicine. He completed his pediatric residency at Children’s National Medical Center in Washington, DC and a fellowship in Pediatric Hematology-Oncology and Pediatric Neuro-Oncology at Memorial Sloan-Kettering Cancer Center in NYC. Dr. Becher served on the faculty at Duke University and Northwestern University prior to relocating to Mount Sinai.
Dr. Becher’s research, funded by the National Institutes of Health (NIH), uses genetically engineered mouse models to identify more effective therapies for children with DIPG, or diffuse intrinsic pontine glioma. DIPG is an incurable childhood brain cancer that arises in the brainstem. Dr. Becher developed the first genetically engineered mouse models for DIPG and co-discovered that 25% of DIPGs harbor somatic activating mutations in a gene called ACVR1 or ALK2, thus identifying a novel therapeutic target. His research team is currently evaluating novel therapies in these models and are also developing novel models for other types of childhood brain cancers. Dr. Becher’s research has been published in top scientific journals, and he serves on the advisory board of several leading pediatric cancer foundations. Dr. Becher has also initiated clinical trials for children with solid tumors evaluating novel therapies.
In addition to directing his research group, Dr. Becher provides patient care as a pediatric hematologist-oncologist and supervises pre- and post-doctoral trainees. He serves as a grant reviewer for several organizations including NIH. Among the numerous awards he has won, he has been named a Damon Runyon Clinical Investigator, a St. Baldrick’s Scholar, a Forbeck Scholar, and a Hyundai Hope on Wheels Scholar.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Research Topics
Pediatrics
Multi-Disciplinary Training Areas
Neuroscience [NEU]
Clinical Focus
- Pediatric Cancer Second Opinion
- Pediatric Hematology Second Opinion
Education
MD, jhusm
Residency, Pediatrics
Children's National Hospital
Fellowship, Pediatric Hematology-Oncology
New York Presbyterian Hospital
Fellowship, Pediatrics
Memorial Sloan-Kettering Cancer Center
Certifications
American Board of Pediatrics
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Pediatric Hematology-Oncology1468 Madison Avenue, 4th Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Becher during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Day One Biopharmaceuticals
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Becher during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Day One Biopharmaceuticals
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.